Reversibility of regorafenib effects in hepatocellular carcinoma cells

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 4, 2013, Pages 869-877

  D'Alessandro, Rosalba ^a   Refolo, Maria G ^a   Lippolis, Catia ^a   Messa, Caterina ^a   Cavallini, Aldo ^a   Rossi, Roberta ^b   Resta, Leonardo ^b   Di Carlo, Antonio ^a   Carr, Brian I ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Growth; Hepatocarcinoma; Migration, invasion; Regorafenib; Reversibility

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BIOLOGICAL MARKER; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; PHYTOMENADIONE; REGORAFENIB; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

ADULT; ARTICLE; AUTOPHAGY; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; WOUND HEALING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOXORUBICIN; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; PHENYLUREA COMPOUNDS; PYRIDINES; VITAMIN K 1;

EID: 84885387350     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2269-8     Document Type: Article

References (34)

1. Ahmad T, Eisen T (2004) Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10:6388S-6392S
2. Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA, Montalto G (2012) Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle 11:2843-2855
3. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
4. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
7. Otsuka T, Eguchi Y, Kawazoe S, Yanagita K, Ario K, Kitahara K, Kawasoe H, Kato H, Mizuta T, The saga liver cancer study group (2012) Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res 42:879-886
8. Edmonds K, Hull D, Spencer-Shaw A, Koldenhof J, Chrysou M, Boers-Doets C, Molassiotis A (2012) Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. Eur J Oncol Nurs 16:172-184
9. Porta C, Paglino C, Imarisio I, Bonomi L (2007) Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 7:127-134
10. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245-255
11. Strumberg D, Schultheis B (2012) Regorafenib and cancer. Expert Opinion Invest Drugs 21:879-889
12. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG, GRID study investigators (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295-302
13. Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, CORRECT Study Group (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312
14. Brahimi F, Rachid Z, Qiu Q, McNamee JP, Li YJ, Tari AM, Jean-Claude BJ (2004) Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA. Int J Cancer 112:484-491
15. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610-2621
16. Steeghs N, Rabelink TJ, Op't Roodt J, Batman E, Cluitmans FH, Weijl NI, de Koning E, Gelderblom H (2010) Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol 21:1100-1105
17. Carr BI, Cavallini A, Lippolis C, D'Alessandro R, Messa C, Refolo MG, Tafaro A (2013) Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence and recovery. J Cell Physiol 228:292-297
18. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J (2010) A chromatin-mediated reversible drug tolerant state in cancer cell subpopulations. Cell 141:69-80
19. Carr BI, D'Alessandro R, Refolo MG, Iacovazzi PA, Lippolis C, Messa C, Cavallini A, Correale M, Di Carlo A (2013) Effects of low concentrations of Regorafenib and Sorafenib on human HCC cell AFP, migration, invasion and growth in vitro. J Cell Physiol 228:1344-1350
20. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239
21. Cao H, Phan H, Yang LX (2012) Improved chemotherapy for hepatocellular carcinoma. Anticancer Res 32:1379-1386
22. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montaná X, Llovet JM, Bruix J (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatology 46:474-481
23. Wei G, Wang M, Hyslop T, Wang Z, Carr BI (2010) Vitamin K enhancement of Sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer 127:2949-2958
24. Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KS (2010) Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 102:1724-1730
25. Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, Daily MF, Shah M, Evers BM (2012) The role of PI3 K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. Anticancer Res 32:2531-2536
26. Ibrahim N, Yu Y, Walsh WR, Yang JL (2012) Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies. Oncol Rep 27:1303-1311
27. Kudo M (2012) Targeted therapy for liver cancer: updated review in 2012. Curr Cancer Drug Targets 12:1062-1072
28. Garlick DS, Greiner DL, Davis RJ (2011) The role of JNK in the development of hepatocellular carcinoma. Genes Dev 25:634-636
29. Bode AM, Dong Z (2007) The functional contrariety of JNK. Mol Carcinog 46:591-598
30. Lee YC, Chang AY, Lin-Feng MH, Tsou WI, Chiang IH, Lai MZ (2012) Paxillin phosphorylation by JNK and p38 is required for NFAT activation. Eur J Immunol 42:2165-2175
31. Zhang YH, Wang SQ, Sun CR, Wang M, Wang B, Tang JW (2011) Inhibition of JNK1 expression decreases migration and invasion of mouse hepatocellular carcinoma cell line in vitro. Med Oncol 28:966-972
32. Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA (2006) Functional coupling of p38-dependent protein kinase-like endoplasmatic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res 66:1702-1710
33. Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathway in cancer development. Nature Rev Cancer 9:537-549
34. Kim JH, Lee SC, Ro J, Kang HS, Kim HS, Yoon S (2010) Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines. Biochem Pharmacol 79:373-380